Fluorescent Label Patents (Class 436/546)
  • Patent number: 11345717
    Abstract: An optical sensing element for use in the detection of hydrogen peroxide includes a sensing compound provided as a coating on a substrate. The sensing compound, on exposure to hydrogen peroxide, forms a luminescent reporter compound when excited with stimulating radiation at a predetermined wavelength that the sensing compound does not absorb.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 31, 2022
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Paul Leslie Burn, Paul Edward Shaw, Shengqiang Fan
  • Patent number: 11092595
    Abstract: Bispyridines improve the labeling of nucleophiles, including amines and thiols and are particularly useful for improving labeling with acidic and basic labels. Use of bispyridines with such labels dramatically increases labeling compared to protocols without a bispyridine. The labeled nucleophile can then be subjected to standard analytical methods.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: August 17, 2021
    Assignee: Agilent Technologies, Inc.
    Inventors: Francis T. Haxo, Michael J. Kimzey
  • Patent number: 10871473
    Abstract: Provided is a method of detecting free mannose and glucose in serum using high performance liquid chromatography. Compared to existing technology, the pretreatment process of samples is simpler, the detection time is shortened, and the detection efficiency is greater. When detection of serum samples is carried out, mannose, rhamnose and glucose may be completely separated, and mannose and glucose will not affect each other during quantification, thereby ensuring the accuracy of detection results.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: December 22, 2020
    Assignee: THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY
    Inventors: Lijuan Zhang, Yong Liu
  • Patent number: 10053622
    Abstract: A composition can include a first moiety capable of being excited to an excited state, and a second moiety capable of accepting excited state energy from the first moiety. The second moiety is capable of emitting light with a FWHM of 15 nm or less when excited. The second moiety can be a J-aggregate and the first moiety can be a semiconductor nanocrystal.
    Type: Grant
    Filed: July 4, 2013
    Date of Patent: August 21, 2018
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Jonathan E. Halpert, Jonathan Tischler, Moungi G. Bawendi, Vladimir Bulovic
  • Patent number: 9944657
    Abstract: The present application discloses a luminescent lanthanide chelate of formula (I) with lanthanides such as europium, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: April 17, 2018
    Assignee: Radiometer Turku Oy
    Inventors: Niko Meltola, Harri Takalo
  • Patent number: 9814788
    Abstract: A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: November 14, 2017
    Assignee: PHARMACOPHOTONICS, INC.
    Inventors: Exing Wang, Daniel Meier, Robert Bunch, Bruce Molitoris, Ruben Sandoval, Matthew Rubin
  • Patent number: 9566355
    Abstract: The present invention relates to bacteria-targeted contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to bacteria targeted MRI contrast agents that can be used to detect bacteria in vivo or in vitro. In certain embodiments, the contrast agents comprise a metal chelate conjugated to at least two Zn-dipicolylamine groups.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: February 14, 2017
    Assignee: Northwestern University
    Inventors: Lauren M. Matosziuk, Allison S. Harney, Keith W. MacRenaris, Thomas J. Meade
  • Patent number: 9289512
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: March 22, 2016
    Assignee: ImmunoGen, Inc.
    Inventor: Wayne C. Widdison
  • Patent number: 9151735
    Abstract: The present invention relates to a novel cyanne derivative having a meso-reaction functional group in a polymethine chain, and a preparation method thereof, and the cyanine derivative having the reaction functional group substituted at the meso site may be suitable for mass production thanks to a very simple synthesis method, have a very fast reaction rate because while a related art reagent for detection of nerve agents undergoes two steps of reactions, the cyanine derivative of the present invention undergoes only one step of reaction, have very excellent sensitivity, and be useful as an acid pH-activated ratiometric NIR probe because it is able to be activated in an acidic pH and is usable in an aqueous environment.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: October 6, 2015
    Assignee: Ewha University-Industry Collaboration Foundation
    Inventors: Juyoung Yoon, Guo Zhiqian
  • Patent number: 9110075
    Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: August 18, 2015
    Assignee: Monogram Biosciences, Inc.
    Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
  • Patent number: 9040310
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: May 26, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Patent number: 9023661
    Abstract: A method for determining the presence or amount of one or more ligands or analytes in a sample including contacting the sample with a biosensor having an environmentally-sensitive dye conjugated to a binding member, wherein the biosensor compound exhibits a detectable color change as a result of binding to the ligand or analyte or as a result of a change in concentration of the ligand or analyte in the sample. The presently disclosed biosensors can be used to detect the presence of or amount of physiologically-important metabolites, such as glucose, fatty acids, and lactate, in biological samples.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: May 5, 2015
    Assignee: Becton, Dickinson and Company
    Inventors: Joseph Thomas, Michael T. Cash
  • Patent number: 9012242
    Abstract: Multivalent fluorescent probes and methods of using these multivalent fluorescent probes for in vitro and in vivo imaging are described.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: April 21, 2015
    Assignee: Caliper Life Sciences
    Inventors: Rajendra Singh, Ning Zhang, Jae Beom Kim, Zhenjun Diwu
  • Patent number: 8999652
    Abstract: Mixtures of cell types can be analyzed by having at least two signal markers, with at least one at three different levels to provide a barcode for each cell type. The mixture of cells may be subjected to a common candidate moiety and the effect of the moiety on the cells determined along with identification of the cell by the barcode. Conveniently, surface marker proteins and labeled antibodies can be used to create the barcode and the cells analyzed with flow cytometry.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: April 7, 2015
    Assignee: Primity Bio, Inc.
    Inventors: Peter Oliver Krutzik, Thomas Scott Wehrman
  • Patent number: 8993350
    Abstract: The present invention relates generally to a novel method using HPLC and fluorescence detection of free PEG-mal in PEGylated proteins and PEG-mal raw materials by adding a fluorescent label to the free PEG-mal.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: March 31, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mei Lin, Anulfo Valdez
  • Patent number: 8969100
    Abstract: Regions where metastatic cancer cells can exist are detected with high accuracy in a sentinel lymph node. Quantum dots are injected into the vicinity of a cancer in a living body, thereby identifying the location of the sentinel lymph node by means of fluorescence. Subsequently, the sentinel lymph node is extracted. With respect to the sentinel lymph node extracted with quantum dots injected, structural analysis is conducted by means of precision fluorescence measurement which uses a confocal fluorescence microscope for monomolecular observation. Specifically, the fluorescence intensity is measured with respect to each of multiple areas in the sentinel lymph nodes, and out of the multiple areas measured, one or more areas are detected as afferent lymph vessel inflow regions in descending order of fluorescence intensity.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: March 3, 2015
    Assignees: Tohoku University, Konica Minolta Medical & Graphic, Inc.
    Inventors: Makoto Hikage, Kohsuke Gonda, Motohiro Takeda, Takashi Kamei, Noriaki Ohuchi, Hideki Gouda, Yasushi Nakano
  • Patent number: 8962342
    Abstract: Nanoparticles comprising surface-enhanced Raman scattering (SERS) reporter molecules of the formula A-Y and methods of their use are disclosed, wherein A is selected from the group consisting of: wherein X1 is CR4 or N; and Y is selected from the group consisting of:
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 24, 2015
    Assignee: Beckton, Dickinson and Company
    Inventors: Joseph Thomas, Rajendra R. Bhat, W. Shannon Dillmore, Douglas B. Sherman
  • Patent number: 8962263
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: February 24, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Patent number: 8957029
    Abstract: The present invention relates to novel peptides capable of binding to action. The peptides are useful in methods for detecting actin in vitro or in living cells.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: February 17, 2015
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Roland Wedlich-Söldner, Michael Sixt, Julia Riedl, Alvaro Crevenna
  • Patent number: 8945857
    Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 3, 2015
    Inventor: John Schrader
  • Patent number: 8932881
    Abstract: New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridane-based compounds and 1,2-dioxetanes. Among the new acridane-based compounds are water-soluble acridanes, enhancer coupled acridanes, bis and tris-acridanes as well as acridane-1,2-dioxetanes. Among the new 1,2-dioxetanes are electron deficient group-containing dioxetanes and tethered bis-1,2-dioxetanes. The 1,2-dioxetanes are useful as substrates for various enzymes. The acridanes can be admixed with an oxidizing agent, an aqueous buffer and, optionally, a stabilizer to form a substrate or reagent formulation useful for assaying, inter alia, HRP.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 13, 2015
    Inventors: Brij Pal Giri, Dinesh Dagli, Pritam Singh
  • Patent number: 8927290
    Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: One Lambda, Inc.
    Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
  • Patent number: 8921124
    Abstract: PROBLEM Provided is a novel cyanine dye derivative with a pyrazole skeleton and an indole skeleton, having high sensitivity performance in a shorter wavelength region as compared with a conventional optical system, and showing high water solubility.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: December 30, 2014
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Matsuhiro Date, Satoshi Hasaba, Naoyuki Yamamoto
  • Patent number: 8906637
    Abstract: The present invention provides method and compositions for detecting target molecules present on cells and tissues. In particular, the methods involve adding primary antibodies such as scFv-targeted lactamase that are directed against a target of interest (e.g., cancer markers) to a tissue sample, followed by adding a lactam-containing compound and finally a lactamase reporter system. In some preferred embodiments, the lactamase reporters are fluorescent reporters that bind to the test tissue. In some particularly preferred embodiments, the test tissue contains at least once cancer cell and/or at least one cancer-associated marker.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: December 9, 2014
    Assignee: Danisco US Inc.
    Inventor: Steven W. Sherwood
  • Patent number: 8889102
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: November 18, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Sean J. Pittock
  • Patent number: 8883514
    Abstract: A enhancing reagent for enhancing chemiluminescence of 1,2-dioxetane compounds and a method for using the enhancing reagent to enhance chemiluminescence are provided, in which the enhancing reagent contains a multi-alkyl quaternary ammonium salt of Formula I. A chemiluminescent composition with a 1,2-dioxetane compound as a substrate and a kit thereof are further provided, which contain a 1,2-dioxetane compound and a multi-alkyl quaternary ammonium salt of Formula I.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: November 11, 2014
    Assignee: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    Inventors: Chungen Qian, Yuping Zhang
  • Patent number: 8883491
    Abstract: The present invention generally relates to systems and methods for counting biomolecules or cells. In certain embodiments, the invention provides a cell counting or biomolecule counting system including: a covered chamber having a known height and configured to hold a suspension of biomolecules or cells in a sample; at least one fluorescent light source connected to at least one fluorescent light beam narrowing device; a bright-field light source connected to a bright-field light beam narrowing device; a microscope objective; a detection device; a fluorescent filter assembly to allow only excitation light to illuminate the sample and allow only emission light from the sample to be imaged by the detection device; and a movable light shutter to block bright-field light during fluorescent detection.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: November 11, 2014
    Assignee: Nexcelom Bioscience LLC
    Inventors: Bo Lin, Peter Y. Li, Jean Qiu, Timothy Smith, Todd Sobolewski, Alnoor Pirani
  • Patent number: 8865420
    Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: October 21, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
  • Patent number: 8865478
    Abstract: Reagents, kits and methods for detecting biological molecules by energy transfer from an activated chemiluminescent substrate to an energy acceptor dye such as a J-aggregated dye are described.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: October 21, 2014
  • Patent number: 8841134
    Abstract: A combination of nanoparticles is disclosed comprised of amine functionalized polyethylene glycol in which one particle with a fluorescent donor dye having one wavelength excitation maximum and at least one additional particle with a second fluorescent dye having a second, higher wavelength excitation maximum, the particles having the same or different biomolecule targeting moieties bound to their external surfaces.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: September 23, 2014
    Assignee: Bruker Biospin Corporation
    Inventors: Rao Papineni, John William Harder, William E. McLaughlin, Douglas Lincoln Vizard, Tao Ji
  • Patent number: 8835183
    Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: September 16, 2014
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: George Bashirians, Deborah Byrne, Sarah Groulx, Sharon Jackson, Heather Lane-Brown, Banumathi Sankaran, Edward Scalice, Karen Yang, Jian Zheng
  • Patent number: 8828671
    Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 9, 2014
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Norman B. Purvis, Gregory T. Stelzer
  • Patent number: 8822695
    Abstract: The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: September 2, 2014
    Assignee: Life Technologies Corporation
    Inventors: Gayle Buller, Jixiang Liu, Stephen Yue, Jolene Bradford
  • Patent number: 8822233
    Abstract: New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridane-based compounds and 1,2-dioxetanes. Among the new acridane-based compounds are water-soluble acridanes, enhancer coupled acridanes, bis and tris-acridanes as well as acridane-1,2-dioxetanes. Among the new 1,2-dioxetanes are electron deficient group-containing dioxetanes and tethered bis-1,2-dioxetanes. The 1,2-dioxetanes are useful as substrates for various enzymes. The acridanes can be admixed with an oxidizing agent. an aqueous buffer and, optionally, a stabilizer to form a substrate or reagent formulation useful for assaying, inter alia, HRP.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: September 2, 2014
    Inventors: Brij Pal Giri, Dinesh Dagli, Pritam Singh
  • Patent number: 8815159
    Abstract: A nanostructured particulate material, which includes a redox active luminescent organic and/or ionic compound, is provided herein. The nanostructured particulate material may be used for determining the presence of an analyte of interest in a sample by detecting the emitted electromagnetic radiation generated by exposing a reagent mixture, which includes the nanostructured material and the target analyte, to chemical or electrochemical energy.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: August 26, 2014
    Assignee: Board of Regents of the University of Texas System
    Inventors: Allen J. Bard, Fu-Ren F. Fan, Jiaguo Yu, Khalid Omer
  • Patent number: 8815527
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: August 26, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Patent number: 8802450
    Abstract: Methods and compositions are provided that include a multichromophore and/or multichromophore complex for identifying a target biomolecule. A sensor biomolecule, for example, an antibody can be covalently linked to the multichromophore. Additionally, a signaling chromophore can be covalently linked to the multichromophore. The arrangement is such that the signaling chromophore is capable of receiving energy from the multichromophore upon excitation of the multichromophore. Since the sensor biomolecule is capable of interacting with the target biomolecule, the multichromophore and/or multichromophore complex can provide enhanced detection signals for a target biomolecule.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: August 12, 2014
    Assignee: Sirigen, Inc.
    Inventors: Brent S. Gaylord, Janice W. Hong, Tsu-Ju Fu, Cheng-Jun Sun, Russell Baldocchi
  • Patent number: 8796040
    Abstract: A system of quantitatively determining a biomolecule, which has: allowing fluorescent silica particles capable of emitting fluorescence detectable by a flow cytometer to capture a target biomolecule fluorescent-labelled for quantitative determination; detecting the fluorescence emitted from the fluorescent silica particles themselves by using the flow cytometer; and measuring the intensity of the fluorescence of the labelled target biomolecule, thereby quantitatively determining the target biomolecule.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: August 5, 2014
    Assignees: The Furukawa Electric Co., Ltd., The University of Tokushima
    Inventors: Hideki Aizawa, Michio Ohkubo, Michihiro Nakamura, Hirokazu Miyoshi
  • Patent number: 8785212
    Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: July 22, 2014
    Assignee: Life Technologies Corporation
    Inventors: Brian Agnew, Kyle Gee, Schuyler Corry
  • Patent number: 8772048
    Abstract: Fluorophores derived from photoactivatable azide-pi-acceptor fluorogens or from a thermal reaction of an azide-pi-acceptor fluorogen with an alkene or alkyne are disclosed. Fluorophores derived from a thermal reaction of an alkyne-pi-acceptor fluorogen with an azide are also disclosed. The fluorophores can readily be activated by light and can be used to label a biomolecule and imaged on a single-molecule level in living cells.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: July 8, 2014
    Assignees: Kent State University, Leland Stanford Junior University
    Inventors: Robert J. Twieg, William E. Moerner, Samuel J. Lord, Na Liu, Reichel Samuel
  • Patent number: 8772047
    Abstract: The presently disclosed subject matter provides thiol-reactive, environmentally sensitive fluorescent dyes, or fluorophores, which have an emission wavelength in the visible spectral region. When conjugated with a binding protein, the fluorophores exhibit a ratiometric response to one or more ligands or target analytes. The presently disclosed fluorophore-binding protein conjugates can be used to detect the presence of or amount of physiologically-important metabolites, such as glucose, fatty acids, and lactate, in biological samples.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: July 8, 2014
    Assignee: Becton, Dickinson and Company
    Inventors: Joseph Thomas, Michael T. Cash
  • Patent number: 8735178
    Abstract: Novel withanolide chemical genetic probes identify the in vivo binding target of withaferin A, which is the intermediate filament type III protein vimentin. In addition, a withanolide-based small molecule screening method screens drug candidates that target intermediate filament type III proteins. The method includes introducing a tagged linker covalently bonded to the withanolide molecule to form a withanolide probe. Better or alternative small molecule compounds as potential drug candidates can be generated based on their likely affinity for the determined binding site in vimentin. The affinity labeled withanolide can also be used to find intermediate filament-associated proteins using chemical proteomics by extracting proteins from cells that were exposed to withanolide-biotin analog. The withanolide probes can be used to monitor expression of vimentin, in tumor samples or other diseased tissues.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: May 27, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Royce Mohan, Paola Bargagna-Mohan, Kyung Bo Kim
  • Patent number: 8729258
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: May 20, 2014
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Todd M. Corneillie, Jide Xu
  • Patent number: 8709830
    Abstract: The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: April 29, 2014
    Assignee: Biotium, Inc.
    Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
  • Patent number: 8710195
    Abstract: A fluorescent protein (bFP) having chemiluminescence activity is a complex composed of the apoprotein of a calcium-binding photoprotein, coelenteramid or an analog thereof, and calcium ions or divalent or trivalent ions that can be substituted for the calcium ions. In the complex, the ratio of the number of molecules of the apoprotein to that of the coelenteramid is 1:1 and the ratio of the number of molecules of the apoprotein to that of the divalent or trivalent ions is 1:1 to 1:4. The fluorescent protein is used as a marker because it catalyzes luminescence of coelenterazine and has fluorescence capability. Removal of calcium ions etc. from this fluorescent protein (bFP) having luminescence activity provides a novel fluorescent protein (gFP). Mixing this gFP with the coelenterazine provides a calcium-binding photoprotein, which emit light instantaneously, enabling use as a marker.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: April 29, 2014
    Assignee: JNC Corporation
    Inventor: Satoshi Inouye
  • Patent number: 8691585
    Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: April 8, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
  • Patent number: 8685752
    Abstract: The invention relates to a method for diagnosing a disease state mediated by pathogenic cells. The method comprises the steps of combining with an ex vivo patient sample a composition comprising a conjugate or complex of the general formula Ab-X, wherein the group Ab comprises a ligand that binds to the pathogenic cells and the group X comprises an imaging agent, and detecting the pathogenic cells that express a receptor for the ligand using flow cytometry.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: April 1, 2014
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Wei He, Sumith A Kularatne
  • Patent number: 8664009
    Abstract: The invention provides methods and compositions for labeling dithiol-containing analytes.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: March 4, 2014
    Assignee: SRI International
    Inventors: Laura Ellen Downs Beaulieu, Mary J. Tanga
  • Patent number: 8658433
    Abstract: Novel azo, azide, and sulfenate photoactive compounds and methods using the compounds for photodiagnostic and/or phototherapeutic procedures. The compounds have the formula E-L-DYE-X—Y, wherein DYE is a photoactive component comprising a photoactive diagnostic agent, a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; Y is a photoactive component comprising a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; E is a targeting component for targeting the compound to an anatomical and/or physiological site of a patient; L is a linking component for linking E to DYE; and X is a linking component for linking DYE to Y.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 25, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Raghavan Rajagopalan, Gary L. Cantrell, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
  • Patent number: 8642357
    Abstract: The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: February 4, 2014
    Assignee: Yale University
    Inventors: Jack A. Elias, Chun Geun Lee